GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-15. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
In tropical and most temperate regions, surplus foods were typically preserved using curing (often by salting) and drying, while means of cold food storage were generally unavailable unless in arctic, subarctic or alpine regions where humans can conveniently harvest natural ice (from glaciers or frozen waterbodies) and/or made use of natural coolness in caves, root cellars and winter weather. In the 19th century, the rise of ice trade enabled the development of cold chains. In the late 19th through mid-20th centuries, mechanical refrigeration was invented, improved and greatly expanded in its reach, and refrigeration has thus rapidly evolved in the forms of temperature-controlled rail cars, refrigerator trucks and the ubiquitous white goods refrigerators and freezers in both stores and average homes in most countries. The introduction of refrigerated rail cars also contributed to the settlement of areas that were not on earlier main transport channels such as rivers, harbors, or valley trails, and sparked the building of large cities which are able to thrive in areas that were otherwise thought to be inhospitable due to hot climate, such as Houston, Texas, and Las Vegas, Nevada. In most developed countries today, cities and towns are heavily dependent upon refrigeration in the food processing, distribution and retail industries (such as supermarkets and butcher shops) to maintain food safety for daily consumption.
Commercial instant soups are manufactured in several types. Some consist of a packet of dry soup stock. These do not contain water, and are prepared by adding water and then heating the product for a short time, or by adding hot water directly to the dry soup mix. Instant soup can also be produced in a dry powder form, such as Unilever's Cup-a-Soup.
A related concept is the 'bill of health', a document issued by officials of a port of departure indicating to the officials of the port of arrival whether it is likely that the ship is carrying a contagious disease, either literally on board as fomites or via its crewmen or passengers. As defined in a consul's handbook from 1879:
Sources: en.wikipedia.org
In the equation above, xi is the concentration of template Ii; x is the total concentration of all templates; ki is the excess production rate of template Ii, which is a difference between formation fi by self-replication of the template and its degradation di, usually by hydrolysis; ki,j is the production rate of template Ii catalysed by Ij; and φ is a dilution flux; which guarantees that the total concentration is constant. Production and degradation rates are expressed in numbers of molecules per time unit at unit concentration (xi = 1). Assuming that at high concentration x the term ki can be neglected, and, moreover, in the hypercycle, a template can be replicated only by itself and the previous member of the cycle, the equation can be simplified to:
=== Applications === IGC experiments have applications over a wide range of industries. Both surface and bulk properties obtained from IGC can yield vital information for materials ranging from pharmaceuticals to carbon nanotubes. Although surface energy experiments are most common, there are a wide range of experimental parameters that can be controlled in IGC, thus allowing the determination of a variety of sample parameters. The below sections highlight how IGC experiments are utilized in several industries.
Paraquat, for instance, structurally resembles metabolized MPTP, which selectively kills dopaminergic neurons by inhibiting mitochondrial complex 1. It is widely used to model PD. A widely used herbicide, Paraquat has been epidemiologically linked to higher Parkinson's risk, and rodent studies show it causes mitochondrial dysfunction, oxidative stress, and dopaminergic neuron loss. Rotenone, a naturally derived insecticide, inhibits mitochondrial complex 1 and selectively damages dopaminergic neurons in the substantia nigra. Rodent studies show both temporary and chronic exposure can produce Parkinson-like pathology, including enteric nervous system changes. The dithiocarbamate fungicide Maneb, the second most commonly used pesticide in Brazil, interferes with mitochondrial respiration.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.